
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences has demonstrated expanding operating margins, outperforming its targeted range, which bodes well for its overall profitability. The company anticipates an average annual sales growth of approximately 10%, driven by an increasing portfolio in structural heart therapies and supportive market conditions. Additionally, favorable clinical outcomes and an anticipated growth in TAVR procedure volumes are expected to enhance the company's financial performance, potentially leading to a higher trading multiple.
Bears say
Edwards Lifesciences faces several fundamental challenges that contribute to a negative outlook on its stock. Key risks include a potentially lower growth outlook for its transcatheter aortic valve replacement (TAVR) business and a lagging innovation pipeline for tricuspid and mitral valve products, which may fail to meet sales expectations. Additionally, external pressures from increased competition, a challenging global regulatory environment, and economic headwinds such as inflation and hospital staffing shortages may hinder the company's ability to expand its market share and achieve revenue growth targets.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares